New RNA drug shows promise for cholesterol control
NCT ID NCT04832971
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2b trial tested an experimental drug called ARO-ANG3 in 204 adults with mixed dyslipidemia, a condition with high triglycerides and cholesterol. Participants received injections of the drug or a placebo over several months. The goal was to see if the drug safely lowers fat levels in the blood, potentially offering a new way to manage heart disease risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ARO-ANG3 (an experimental RNA-targeted drug given as an injection)
What this could lead to
If successful, this could lead to a new treatment option for people with mixed dyslipidemia to better control their cholesterol and triglyceride levels.
What could go wrong
This is a mid-stage trial with only 204 participants, so results may not apply to everyone. The drug is still experimental, and its long-term safety and effectiveness are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIXED DYSLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Marion, Ohio, 43302, United States
-
Research Site 10
Omaha, Nebraska, 68114, United States
-
Research Site 11
Houston, Texas, 77030, United States
-
Research Site 12
Québec, G1G 3Z4, Canada
-
Research Site 13
Christchurch, 8011, New Zealand
-
Research Site 14
Rotorua, 3010, New Zealand
-
Research Site 15
Greensboro, North Carolina, 27408, United States
-
Research Site 16
Chicoutimi, Quebec, G7H 7K9, Canada
-
Research Site 17
Miami, Florida, 33144, United States
-
Research Site 18
Nedlands, 6009, Australia
-
Research Site 19
Birkenhead, 0626, New Zealand
-
Research Site 2
Morehead City, North Carolina, 28557, United States
-
Research Site 20
Hamilton, 3200, New Zealand
-
Research Site 21
Sippy Downs, Queensland, 4556, Australia
-
Research Site 22
New York, New York, 10029, United States
-
Research Site 23
Las Vegas, Nevada, 89121, United States
-
Research Site 24
Minneapolis, Minnesota, 55455, United States
-
Research Site 25
London, Ontario, N6A 5A5, Canada
-
Research Site 4
Camp Hill, Pennsylvania, 17011, United States
-
Research Site 5
Huntington Park, California, 90255, United States
-
Research Site 6
Blacktown, New South Wales, 2148, Australia
-
Research Site 7
Hialeah, Florida, 33012, United States
-
Research Site 8
Port Orange, Florida, 32127, United States
-
Research Site 9
Québec, H7T2P5, Canada